[1] |
Sunitinib for the treatment of gastrointestinal stroma tumours[Z]. NICE technology appraisal guidance 179, 2009.
|
[2] |
White IR. Uses and limitations of randomization?based efficacy estimators[J]. Stat Methods Med Res, 2005, 14(4): 327?347.
|
[3] |
Lee YJ, Ellenberg JH, Hirtz DG, et al. Analysis of clinical trials by treatment actually received: is it really an option [J]? Stat Med, 1991, 10(10): 1595?1605.
|
[4] |
Law MG, Kaldor JM. Survival analyses of randomized clinical trials adjusted for patients who switch treatments[J]. Stat Med, 1996, 15(19): 2069?2076.
|
[5] |
Loeys T, Goetghebeur E. A causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all?or?nothing compliance[J]. Biometrics, 2003, 59(1): 100?105.
|
[6] |
Robins JM, Tsiatis AA. Correcting for non?compliance in randomized trials using rank preserving structural failure time models[J]. Commun Stat?Theor M, 1991, 20(8): 2609?2631.
|
[7] |
Branson M, Whitehead J. Estimating a treatment effect in survival studies in which patients switch treatment[J]. Stat Med, 2002, 21(17): 2449?2463.
|
[8] |
Walker AS, White IR, Babiker AG. Parametric randomization?based methods for correcting for treatment changes in the assessment of the causal effect of treatment[J]. Stat Med, 2004, 23(4): 571?590.
|
[9] |
Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log?rank tests[J]. Biometrics, 2000, 56(3): 779?788.
|
[10] |
Shao J, Chang M, Chow SC. Statistical inference for cancer trials with treatment switching[J]. Stat Med, 2005, 24(12): 1783?1790.
|
[11] |
Joffe MM, Hoover DR, Jacobson LP, et al. Estimating the effect of zidovudine on Kaposi's sarcoma from observational data using a rank preserving structural failure?time model[J]. Stat Med, 1998, 17(10): 1073?1102.
|
[12] |
Mark SD, Robins JM. Estimating the causal effect of smoking cessation in the presence of confounding factors using a rank preserving structural failure time model[J]. Stat Med, 1993, 12(17): 1605?1628.
|
[13] |
Mark SD, Robins JM. A method for the analysis of randomised trials with compliance information: an application to the multiple risk factor intervention trial[J]. Control Clin Trials, 1993, 14(2): 79?97.
|
[14] |
White IR, Babiker AG, Walker S, et al. Randomization?based methods for correcting for treatment changes: examples from the Concorde trial[J]. Stat Med, 1999, 18(19): 2617?2634.
|
[15] |
GSK. Pazopanib (Votrient) for the first?line treatment of patients with advanced renal cell carcinoma (RCC)[Z]. ADDENDUM to GSK'S SUBMISSION TO NICE 20 JULY 2010.
|
[16] |
Collett D. Modelling survival data in medical research[Z]. Chapman and Hall, 2003.
|
[17] |
White IR, Walker S, Babiker A. Strbee: randomization?based efficacy estimator[J]. Stata J, 2002, 2(2): 140?150.
|
[18] |
Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer[Z]. NICE,2002.
|